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OBJECTIVES This study was performed to determine whether angiotensin converting enzyme (ACE)
inhibition improves endothelium-dependent flow-mediated vasodilation in patients with
atherosclerosis or its risk factors and whether this is mediated by enhanced bradykinin
activity.
BACKGROUND Abnormal coronary vasomotion due to endothelial dysfunction contributes to myocardial
ischemia in patients with atherosclerosis, and its reversal may have an antiischemic action.
Previous studies have shown that ACE inhibition improves coronary endothelial responses to
acetylcholine, but whether this is accompanied by improved responses to shear stress remains
unknown.
METHODS In 19 patients with mild atherosclerosis, metabolic vasodilation was assessed during cardiac
pacing. Pacing was repeated during separate intracoronary infusions of low-dose bradykinin
(BK) and enalaprilat. Endothelium-dependent and -independent vasodilation was estimated
with intracoronary BK and sodium nitroprusside respectively.
RESULTS Enalaprilat did not alter either resting coronary vascular tone or dilation with sodium
nitroprusside, but potentiated BK-mediated dilation. Epicardial segments that constricted
abnormally with pacing (25 6 1%) dilated (3 6 2%) with pacing in the presence of
enalaprilat (p 5 0.002). Similarly, BK at a concentration (62.5 ng/min) that did not alter
resting diameter in the constricting segments also improved the abnormal response to a 6 6
1% dilation (p , 0.001). Cardiac pacing-induced reduction in coronary vascular resistance of
27 6 4% (p , 0.001) remained unchanged after enalaprilat.
CONCLUSIONS Thus ACE inhibition: A) selectively improved endothelium-dependent but not -independent
dilation, and B) abolished abnormal flow-mediated epicardial vasomotion in patients with
endothelial dysfunction, in part, by increasing endogenous BK activity. (J Am Coll Cardiol
1999;33:796–804) © 1999 by the American College of Cardiology
Exercise and cardiac pacing dilate human coronary epicar-
dial arteries and microvessels in normal individuals, and the
resulting augmentation in blood flow serves to meet the
increased myocardial oxygen requirements (1–5). The vas-
cular endothelium is pivotal in regulating this vasomotion
by the release of a variety of relaxing and constricting factors
(6–8). One important endothelium-derived relaxing factor
is nitric oxide (NO) or an adduct of NO (9,10) that
contributes almost entirely to epicardial and, to a lesser
extent, microvascular dilation during metabolic stress. Ath-
erosclerosis and its risk factors are associated with depressed
microvascular dilator responses and paradoxical constriction
of epicardial arteries with exercise and cardiac pacing which
may contribute to the pathogenesis of myocardial ischemia
in these patients (1–3,5,11). Endothelial cell dysfunction
associated with reduced NO activity is believed to be the
major underlying cause for this abnormal vasomotion, and,
thus, interventions which ameliorate endothelial dysfunc-
tion and increase NO bioavailability are likely to improve
coronary vasomotion and reduce myocardial ischemia in
patients with coronary atherosclerosis.
A potential therapeutic target for improving endothelial
dysfunction appears to be the inhibition of the angiotensin
converting enzyme (ACE/kininase II). This enzyme,
present in large quantities on the surface of endothelial cells,
is a key component of the circulating and vascular
kallikrein-kinin and the renin-angiotensin systems. One of
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its functions is to degrade bradykinin (BK), a locally
synthesized polypeptide that is known to regulate resting
tone and flow-mediated vasodilation in the normal human
coronary circulation (12), possibly through the release of
NO (13,14), prostacyclin (15) and endothelium-derived
hyperpolarizing factor (16). Thus, inhibition of ACE would
increase BK activity and potentially improve endothelial
function, especially if BK activity is depressed in atheroscle-
rosis. In addition to its effects on BK metabolism, ACE also
promotes the synthesis of angiotensin II from angiotensin I,
which among several actions, also stimulates vascular super-
oxide generation (17,18). Thus, ACE inhibition may rectify
endothelial dysfunction by reducing angiotensin II synthesis
and thus attenuating vascular oxidant stress. In this study,
we investigated whether: A) ACE inhibition improves shear
stress-induced (physiological) vasodilation in patients with
mild coronary atherosclerosis or its risk factors, and B) any
observed improvement in vasomotion is mediated by in-
creased BK activity.
METHODS
Patients. We studied 19 patients with angiographically
normal, or near normal (,30% narrowing) coronary arter-
ies, undergoing diagnostic cardiac catheterization for inves-
tigation of chest pain or abnormal noninvasive tests. Pa-
tients with myocardial infarction in the previous month,
valvular heart disease or those treated with ACE inhibitors
in the previous two weeks were excluded. The mean age was
50 6 10 years; there were 15 (79%) men. Eight patients
were hypertensive (blood pressure .140/90 mm Hg), hy-
percholesterolemia (total cholesterol .200 mg/dl) was
present in 14 patients and 2 had diabetes (both on pharma-
cologic antidiabetic therapy). Seven patients were either
current smokers or had smoked in the previous 2 years; 13
patients were exposed to 1, and 6 patients to .1 risk factors.
Angiographic atherosclerosis was present in 11 patients.
Cardiac medications were withdrawn for at least 48 h, and
aspirin a week before the study. The study was approved by
the National Heart, Lung, and Blood Investigational Re-
view Board and informed written consent was obtained
from all patients.
Protocol. After completion of diagnostic coronary arte-
riography, a six-French guide catheter was introduced into
the coronary artery and blood flow velocity was measured
using a 0.018 inch wire equipped with a Doppler crystal at
its tip (Cardiometrics Flowire, Cardiometrics, Inc., Moun-
tain View, California) (19,20). Quantitative angiography
was performed with the ARTREK software (ImageComm
Systems, Inc.). A total of 50 segments were analyzed; 3
segments of epicardial coronary arteries could be measured
in 13 patients, 2 segments in 5 patients, 1 segment in 1
patient. Coronary blood flow and resistance were calculated
as described previously (1,21). All drugs were infused
directly into the left main coronary artery via the guide
catheter at infusion rates ranging between 1 to 2 ml/min.
Infusion rates were halved for studies performed in the right
coronary artery.
After a five-minute infusion of dextrose 5% at 1 ml/min,
baseline coronary blood flow velocity was measured and
coronary angiography performed. Rapid atrial pacing was
performed in 17 patients at heart rates ranging between 130
to 150 bpm. Pacing from the right ventricle was performed
at 150 bpm in the remaining two patients who developed
atrioventricular Wenckebach at rates below 115 bpm. Thus
the mean cardiac pacing rate was 144 6 7 bpm.
Endothelium-dependent vasodilation was estimated in
all patients by performing a dose-response curve with
incremental infusions of intracoronary BK starting at
62.5 ng/min (n 5 19) for 3 min, followed by 2-min
infusions of 1 mg/min (n 5 17) and 4 mg/min (n 5 19).
Five minutes after performing the dose-response curve
with BK, endothelium-independent function was estimated
with sodium nitroprusside and flow reserve with adenosine.
Intracoronary sodium nitroprusside was given at 40 mg/min
for 3 min, and intracoronary adenosine at 2.2 mg/min for
2 min.
After a 15-min interval, an infusion of BK (62.5 ng/min)
was given and pacing was repeated during the infusion.
Following a 10-min recovery period, baseline measurements
were made. Intracoronary enalaprilat, a potent ACE inhib-
itor, was then infused at 20 mg/min for 10 min. In a
previous study, this intravascular concentration of enala-
prilat adequately blocked the constrictor response to
angiotensin I (22). While continuing the infusion, pacing
was repeated at the control rate in all the patients, BK
(62.5 ng/min, n 5 17) was co-infused for 2 min, and 40
mg/min sodium nitroprusside was given for 3 min (n 5
11). Blood flow velocity was measured and coronary
angiography was performed after each intervention.
Statistical analysis. Data are expressed as mean 6 SEM.
Differences between means were compared by paired or
unpaired Student t test, as appropriate. The effect of
multiple doses of BK were analyzed using the two-way
analysis of variance (ANOVA). Appropriate interaction
(dose X drug) tests were employed. All P values are
two-tailed, and a value ,0.05 was considered of statistical
significance. Correlation analysis was performed using Pear-
son’s correlation coefficient.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BK 5 bradykinin
NO 5 nitric oxide
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RESULTS
Effect of enalaprilat on endothelium-dependent and
-independent epicardial coronary artery responses. Rest-
ing mean coronary epicardial diameter remained unchanged
10 minutes after infusion of enalaprilat; 2.1 6 0.1 versus
2.0 6 0.1 mm (p 5 ns), suggesting that ACE did not
regulate resting epicardial vessel tone. There was also no
alteration in mean arterial blood pressure (105 6 2 to 106 6
2 mm Hg) and heart rate (79 6 2 to 81 6 3 bpm).
Epicardial diameter increased progressively with the
62.5 ng/min, 1 mg/min, and 4 mg/min doses of BK by
1.5 6 1%, 8.3 6 1% and 11.4 6 1%, respectively (p ,
0.001, ANOVA). When the 62.5 ng/min dose of BK was
coinfused with enalaprilat, the response was enhanced to
a 5.6 6 1% (p , 0.001) increase in epicardial diameter
(Fig. 1). In contrast, dilation of epicardial coronary
arteries with sodium nitroprusside was similar before and after
enalaprilat (p 5 0.2) (Fig. 1). Thus, enalaprilat significantly
potentiated BK- but not sodium nitroprusside-mediated epi-
cardial vasodilation.
Effect of enalaprilat on pacing-induced coronary epicar-
dial changes. During control pacing, epicardial coronary
artery diameter increased by a mean 3.7 6 1% (p 5 0.06) in
the 50 segments analyzed in 19 patients. After enalaprilat,
there was no significant further increase in pacing-mediated
epicardial vasodilation (5.8 6 2%, p 5 0.4, compared with
control). Further analysis was performed in the 20 segments
from 12 patients that constricted (abnormal response) and
the 30 segments from 16 patients that dilated (normal
response) with pacing (Fig. 2). A mean 5.1 6 1% constric-
tion observed during control pacing improved to a 6.1 6 2%
dilation when pacing was repeated in the presence of
enalaprilat (p 5 0.002, Fig. 2). In contrast, enalaprilat did
not further potentiate the 9.6 6 1% dilation observed in the
dilating segments (Fig. 2). Thus, ACE inhibition selectively
improved epicardial dilation in segments with abnormal
pacing-mediated vasomotion.
Effect of BK and sodium nitroprusside on epicardial
segments with abnormal vasomotion during pacing. Bra-
dykinin (62.5 ng/min) produced no vasodilation (0 6 2%)
in the segments that constricted abnormally with pacing,
compared with a 4.9 6 2% (p 5 0.003) dilation in segments
that dilated normally during pacing (Fig. 3). In contrast,
vasodilation with sodium nitroprusside was similar in the
constricting and dilating segments; 19 6 3% and 20 6 3%,
respectively, p 5 0.9. Enalaprilat enhanced BK-mediated
epicardial vasodilation in both constricting and dilating
segments (11.6 6 3%, p , 0.001 and 10.7 6 3%, respec-
tively, p 5 0.04, Fig. 3). Thus, segments of epicardial
coronary arteries with abnormal pacing-mediated vasomo-
tion demonstrated abnormal reactivity to endothelium-
dependent, but not endothelium-independent vasodilators,
and ACE inhibition improved BK-mediated dilation in
both groups.
Effects of low-dose BK on pacing-induced epicardial
vasomotion. To investigate whether the improvement of
epicardial constriction during pacing by enalaprilat was
secondary to increased local BK levels, we studied the effects
on pacing-induced epicardial vasomotion of low-dose BK at
a concentration that did not alter resting diameter in the
constricting segments. Segments that initially constricted by
5.1 6 1% during pacing, dilated by 5.9 6 1% (p , 0.001)
during pacing with BK (62.5 ng/ml, Fig. 4). Segments of
epicardial coronary arteries that initially dilated with pacing
also dilated with BK and there was no further change during
pacing with BK (Fig. 4). Thus, BK selectively improved
Figure 1. Effects of bradykinin (left) and sodium nitroprusside (right) before (control, ●) and after enalaprilat (C) on epicardial diameter.
(Data represent mean 6 SEM).
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abnormal pacing-induced vasomotion in segments with
endothelial dysfunction, mimicking the action of enalapri-
lat.
Effect of enalaprilat on coronary microvascular function.
Resting mean coronary blood flow and vascular resistance
remained unchanged 10 min after infusion of enalaprilat;
39 6 4 ml/min and 3.3 6 0.4 mm Hgzml21zmin before,
versus 39 6 4 ml/min and 3.2 6 0.3 mm Hgzml21zmin
after, respectively (p 5 ns for all), suggesting that ACE did
not regulate resting coronary microvascular tone. Bradyki-
nin produced graded increases in coronary blood flow and
reduction in vascular resistance; at the 62.5 ng/min,
1 mg/min and 4 mg/min doses; mean blood flow increased
by 14 6 3%, 79 6 9% and 162 6 18%, respectively, and
vascular resistance decreased by 10 6 2%, 41 6 4% and
58 6 4%, respectively, (p , 0.001, ANOVA, both).
Enalaprilat enhanced the response of BK (62.5 ng/min) to
a 40 6 13% (p 5 0.08) increase in flow and a 25 6 5% (p 5
0.02) reduction in vascular resistance, indicating inhibition
of coronary ACE with enalaprilat. In contrast, the 137 6
19% increase in coronary blood flow and 62 6 2% reduction
in vascular resistance with sodium nitroprusside remained
unaltered after enalaprilat (146 6 19% [p 5 0.5] and 61 6
3% [p 5 0.6]) change, respectively.
Figure 2. The effects of cardiac pacing before and after enalaprilat on coronary epicardial segments that initially constricted (left, n 5 20)
or dilated (right, n 5 30) with cardiac pacing. There was no significant difference (p 5 0.5) between the mean baseline diameters of
constricting segments (2.1 6 0.1 mm) compared to dilating segments (2.0 6 0.1 mm). Data represent mean 6 SEM.
Figure 3. The effects of bradykinin (left) and sodium nitroprusside (right) on coronary epicardial segments that constricted or dilated with
cardiac pacing. The potentiation of bradykinin by enalaprilat is demonstrated in hatched bars. Data represent mean 6 SEM.
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During initial cardiac pacing, coronary blood flow in-
creased by 54 6 10% and vascular resistance decreased by
27 6 4%. In the presence of enalaprilat, these indices were
not significantly different at 47 6 9% (p 5 0.5) and 27 6
5% (p 5 0.9), respectively. There was also no correlation
between the magnitude of reduction in vascular resistance
with control pacing and the change observed when pacing
was repeated in the presence of enalaprilat (r 5 0.2, p 5
NS). Thus, ACE inhibition did not influence pacing-
mediated metabolic coronary microvascular dilation in pa-
tients with depressed responses. Furthermore, pacing-
induced microvascular vasodilation was similar in patients
with epicardial vessel constriction and those with dilation
during pacing (52 6 10% vs. 55 6 11% [p 5 ns] increase in
flow with pacing). Finally, flow reserve with adenosine was
similar in both groups (345 6 44% vs 324 6 24% increase
in flow in patients with epicardial dilation and constriction,
respectively).
DISCUSSION
Coronary epicardial and microvascular dilation accompanies
increases in myocardial oxygen demand. Whereas epicardial
dilation is primarily believed to be due to endothelium-
dependent release of NO (1,21,23,24), the causes for mi-
crovascular dilation are multifactorial in origin (25,26).
Endothelial dysfunction associated with diminished NO
activity in patients with atherosclerosis, or those with
normal coronary arteries and risk factors for atherosclerosis,
results in absence of flow-mediated dilation (1). In epicar-
dial coronary arteries of these patients, increased shear
precipitated by exercise, pacing or mental stress causes
paradoxical coronary constriction, probably as a result of
unopposed myogenic constriction (2,3,5,11). In a previous
study, we observed that acute ACE inhibition improves
acetylcholine-mediated, endothelium-dependent dilation
and that this is in part achieved by increased NO bioavail-
ability (27). In this study, we evaluated the effects of ACE
inhibition and BK on coronary vasomotion during stress.
Our data show that: 1) ACE inhibition improves endothe-
lial dysfunction and abolishes abnormal epicardial coronary
artery constriction during cardiac pacing, 2) low-dose BK
also abolishes coronary constriction during pacing, and 3)
ACE inhibition did not influence microvascular dilation
during stress.
Improvement in flow-mediated epicardial vasomotion by
ACE inhibition. As previously reported, cardiac pacing
produced a heterogenous epicardial coronary arterial re-
sponse where some segments dilated and others either
constricted or remained unchanged. Often constriction and
dilation in different segments of epicardial coronary arteries
occurred in the same patients. This heterogenous response
of epicardial coronary arteries to endothelium-dependent
stimuli has been observed previously (28,29) and highlights
the patchy nature of vascular endothelial dysfunction in
coronary conductance vessels of patients with atherosclerosis
or its risk factors.
In order to evaluate endothelial function of segments that
constricted or dilated during pacing, we assessed the effects
of BK, an endothelium-dependent vasodilator, and sodium
nitroprusside, an endothelium-independent agonist. Seg-
ments that constricted with pacing did not dilate with BK,
whereas those that reacted normally to pacing by dilating
also dilated with BK. In contrast, both dilating and con-
stricting segments relaxed equally with sodium nitroprus-
side, indicating that endothelial, but not smooth muscle
function, was abnormal in segments which constricted with
pacing. This is in keeping with animal studies where
Figure 4. The effects of cardiac pacing before and after 62.5 ng/min of intracoronary bradykinin on coronary epicardial segments which
constricted (left) or dilated (right) with control pacing. Data represent mean 6 SEM.
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endothelial damage following balloon injury to the canine
coronary arteries resulted in marked vasoconstriction during
exercise (30). Similarly, in humans, an attenuated vasodila-
tor response to acetylcholine in patients with endothelial
dysfunction is associated with a depressed dilator response
to pacing (31).
The effect of enalaprilat was specific for the endothelium-
dependent vasodilator, BK, and was greater in segments
that initially did not dilate with BK (endothelial dysfunc-
tion) compared to those that dilated (normal endothelial
function). Thus, after ACE inhibition, both segments
dilated to a comparable degree. Similar changes were
observed with ACE inhibition during cardiac pacing. The
beneficial effect of ACE inhibition was restricted to seg-
ments with endothelial dysfunction, where pacing after
enalaprilat abolished epicardial constriction. In contrast,
segments which initially dilated normally with pacing re-
mained unchanged after enalaprilat. However, there was no
difference in the magnitude of increase in flow and, hence,
shear stress between the two groups to account for the
observed difference in epicardial arterial response. These
findings are in agreement with a previous study where acute
infusion of the ACE inhibitor, perindoprilat, improved cold
presser-mediated epicardial coronary constriction (32).
Improvement in coronary endothelial function by ACE
inhibition. As reported previously, acute ACE inhibition
with enalaprilat did not alter basal coronary vascular tone
(22,32,33). However, it is not possible to conclude from this
observation that local generation of angiotensin II by
vascular ACE or enalaprilat-mediated increased endoge-
nous BK availability do not contribute to resting tone. Since
resting coronary vascular tone is tightly autoregulated, it is
possible that reduced angiotensin II-mediated constriction
and BK-mediated dilation is offset by changes in other
endogenous dilators and constrictors.
In the present study, enalaprilat potentiated epicardial
and microvascular dilation in response to BK, but not to
sodium nitroprusside, suggesting that it can selectively
improve endothelium-dependent but not -independent va-
sodilation. Potentiation of BK responses also confirms that
acute administration of enalaprilat achieved adequate inhi-
bition of coronary ACE. Because BK is metabolized by
kininase II or endothelial ACE, improvement of the BK
response by enalaprilat would be expected and would not
necessarily indicate global improvement in endothelial func-
tion. However, in a previous study, we have also demon-
strated improved acetylcholine responses with enalaprilat,
an effect that was due to increased NO bioactivity (27), a
finding confirmed by the TREND investigators using oral
quinapril (34). Data from studies in the human forearm
circulation of patients with mild heart failure (35) and the
femoral circulation of patients with atherosclerosis (36)
confirms a similar action of ACE inhibition on peripheral
vascular endothelial dysfunction.
Mechanism underlying the improvement in flow-
mediated epicardial vasomotion by ACE inhibition: role
of BK. There are at least two important mechanisms
whereby ACE inhibition may improve endothelial NO
activity. By reducing vascular angiotensin II production, it
can increase bioavailability of NO as angiotensin II is a
powerful stimulus for NADH/NADPH oxidase-dependent
vascular superoxide anion generation (17,18). Increased
vascular oxidant level inactivates endothelial NO, a mech-
anism that appears to be instrumental in precipitating
endothelial dysfunction in hypercholesterolemia, atheroscle-
rosis, hypertension and diabetes (37–40). The second pos-
sible mechanism underlying the beneficial effects of ACE
inhibition is by elevation of vascular BK levels that will
directly stimulate the NO pathway.
Although the precise mechanism whereby the endothe-
lium senses and transduces the stimulus of flow and shear
stress is unknown, the possibility that BK may play a key
role in mediating tonic basal and flow-stimulated release of
NO was suggested by recent studies. Epicardial constriction
and inhibition of flow-mediated epicardial dilation in the
human coronary circulation was observed during inhibition
of endogenous BK activity with icatibant, a specific B2
receptor antagonist (12). In our study, we investigated
whether the observed improvement in flow-mediated con-
striction by ACE inhibition was a result of increased BK
activity by repeating pacing during a low-dose infusion of
BK that in itself did not change epicardial diameter in the
segments with dysfunction. Pacing-induced constriction
was abolished by low-dose BK, whereas segments that
initially dilated with pacing, and, hence, had normal endo-
thelial function, had no effect. These observations allow us
to speculate that coronary endothelial dysfunction results in
diminished endogenous kinin activity during stress, which
can be overcome by either exogenous BK or by ACE
inhibition, and that the beneficial effect of ACE inhibitors
is, at least partly, due to enhanced BK activity. This is
further supported by a recent study in normal volunteers
which demonstrated that B2 receptor inhibition abolishes
the potentiation of flow-mediated dilation of the radial
artery by quinaprilat (41).
The observation that BK and ACE inhibition does not
affect epicardial diameter in constricting segments at rest,
yet improves flow-mediated dilation with pacing, needs
explanation. One explanation is that there is up-regulation
of vascular ACE in these segments as described in animal
models of atherosclerosis and in humans (42,43). Thus, low
dose BK is metabolized rapidly resulting in no baseline
effect; however, during increasing shear, there is likely to be
increased availability of BK as a result of its shear-mediated
production. This increased endogenous production in the
setting of either ACE inhibition or low-dose BK infusion is
able to reverse the flow-mediated constriction. In the
dilating segments, there is no up regulation of ACE and,
thus, no limitation in BK production during stress. Thus,
enhancement does not occur. Alternatively, basal and shear-
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mediated NO production by the BK pathway may have
different thresholds and are affected differentially by athero-
sclerosis and its risk factors, a possibility that is worthy of
further study.
Angiotensin-converting enzyme inhibition and micro-
vascular coronary dilation during stress. Cardiac pacing
significantly reduced coronary vascular resistance, but this
was not altered by enalaprilat in either patients with, or
those without, depressed pacing-induced microvascular di-
lation. Our data indicates that, unlike epicardial vasomo-
tion, microvascular metabolic dilation is not potentiated by
ACE inhibition in patients with atherosclerosis or its risk
factors. This was observed despite improvement in BK-
mediated microvascular responses in these patients, and,
therefore, deserves explanation.
That metabolic coronary microvascular dilation is, at least
partly, dependent on endothelium-derived NO activity has
been demonstrated by us in a previous study (1). L-NG,
monomethyl arginine, an inhibitor of NO synthesis, partly
inhibited pacing-induced increase in coronary blood flow in
patients with normal endothelial function, but this contri-
bution of NO was reduced in those with endothelial
dysfunction. In contrast to its partial effects on the mi-
crovessels, NO synthase inhibition completely inhibited
pacing-mediated epicardial coronary dilation, indicating
that conductance vessel dilation is almost entirely, and
microvascular dilation only partially dependent on endothe-
lial NO (44). Coronary microvascular dilation during pacing
in addition to NO is also mediated by release of local
metabolites including adenosine, prostaglandins, carbon
dioxide, hypoxia and is partly due to circulating cat-
echolamines and withdrawal of sympathetic tone (44).
Additionally, these multiple mechanisms may compensate
for any deficiency in NO activity in patients with endothe-
lial dysfunction because of the known autoregulatory capac-
ity of the coronary microcirculation (25,26,44). Further-
more, cardiac pacing is not a maximal shear stress-
producing stimulus, as coronary blood flow on average only
increases by 50% with cardiac pacing. It is possible that
during conditions where blood flow increases are near the
maximum vasodilatory capacity of the human coronary
microvessels, the importance of an intact NO pathway will
become evident. Thus, unlike BK or acetylcholine-mediated
dilation, which is predominantly endothelium-dependent,
pacing-induced microvascular dilation is only in a small part
NO-dependent. Since ACE inhibition selectively improves
endothelium-dependent vasodilation, these differences may
explain the lack of potentiation of microvascular dilation in
the present study compared to previous studies in which
augmentation of endothelium-dependent acetylcholine-
mediated microvascular dilation has been observed (27,45).
Limitations. In this study we did not use a BK receptor
antagonist to investigate the contribution of kinins in the
action of ACE inhibitors. Though this would have been the
most desirable approach, no suitable agent was available for
clinical use. Our study did not include vessels with .50%
stenosis and thus we cannot conclude from our data whether
ACE inhibition would also improve flow-mediated vaso-
motion in vessels with more severe atherosclerosis. Results
from trials in progress examining the effect of ACE inhib-
itors in myocardial ischemia will help clarify this issue (46).
Our study was also not designed to evaluate whether an
increase in NO activity is responsible for the beneficial effect
of ACE inhibition on flow-mediated dilation, but the
finding that improvement in acetylcholine- and BK-
mediated coronary and peripheral dilation is due to in-
creased NO activity in our previous studies suggests that this
is the most likely explanation for the observed changes
(27,36). Due to limited number of patients studied, we are
unable to investigate whether the beneficial effects of ACE
inhibitors are more likely to occur in patients with one or
other of the specific risk factors for atherosclerosis. This
issue needs to be tested in specific subsets of patients.
Conclusions. Abnormal epicardial flow-mediated vasomo-
tion is associated with endothelial dysfunction in patients
with atherosclerosis and its risk factors. Angiotensin-
converting enzyme inhibition selectively improves
endothelium-dependent, but not -independent dilation.
Furthermore, ACE inhibition abolishes abnormal flow-
mediated epicardial vasomotion in patients with endothelial
dysfunction, but it does not influence microvascular dilation
during pacing in patients with diffuse but nonstenotic
epicardial coronary artery disease. This improvement in
epicardial constriction with ACE inhibition is likely to be
mediated, in part, by an increase in endogenous BK activity.
Improvement in abnormal coronary vasomotion during
stress with ACE inhibitors may result in amelioration of
myocardial ischemia in patients with coronary artery disease.
Their long-term effects in enhancing vascular NO activity
provides a pathophysiologic basis for the observed anti-
thrombotic effect of ACE inhibitors and point to a potential
role of these agents in arresting the progression of athero-
sclerosis.
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